Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

pharma regulation

- PMLiVE

PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis

Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

The genetic blood disorder affects more than 800,000 people globally

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

Ipsen’s Kayfanda granted EC approval to treat cholestatic pruritus in Alagille syndrome

The rare genetic disorder affects approximately three in every 100,000 births globally

EU flag

EC approves Bavarian Nordic’s mpox vaccine Imvanex for use in adolescents

More than 120 countries have confirmed over 103,000 cases of mpox since the global outbreak began in 2022

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Janssen wins European approval for Symtuza

European Commission approves the drug to treat HIV-1

- PMLiVE

A baptism of fire for Europe’s new health commissioner

Controversial trade deals, the spread of Ebola and the threat of austerity are just three of the issues facing Dr Vytenis Andriukaitis

EU flag

Life expectancy continues to rise in Europe

EC report shows five-year improvement since 1990

- PMLiVE

EU boost for GSK’s Ebola vaccine research

And EMA says it' poised to assess possible vaccines or treatments

EU flag

EC sets out its pharma priorities

New strategy puts the industry at the heart of Europe’s economic growth prospects, saysEFPIA

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links